Additionally, we showed that this strategy is able to predict signaling pathway adaptations that can be used to define rational combination therapies, as shown for combined MEK and VEGFR-2 inhibition in pediatric MLL-rearranged AML [29]. This evidence concerns the gene KMT2A and acute myeloid leukemia.